泼尼松, 99%,Prednisone

产品编号:西域试剂-WR383235| CAS NO:53-03-2| MDL NO:MFCD00003608| 分子式:C21H26O5| 分子量:358.43

Prednisone (Adasone)是皮质类固醇试剂,有免疫抑制作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
西域试剂-WR383235
55.00 杭州 北京(现货)
西域试剂-WR383235
202.00 杭州 北京(现货)
西域试剂-WR383235
678.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

产品名称泼尼松, 99%
英文名称Prednisone
CAS编号53-03-2
产品描述Prednisone (Adasone)是皮质类固醇试剂,有免疫抑制作用。
产品熔点236-238 °C(lit.)
产品沸点573.7±50.0 °C at 760 mmHg
产品密度1.3±0.1 g/cm3
产品闪点314.8±26.6 °C
精确质量358.178009
PSA91.67000
LogP1.57
外观性状白色结晶粉末
蒸气压0.0±3.6 mmHg at 25°C
折射率1.604
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (348.74 mM; ultrasonic and warming and heat to 80°C)

H2O : 1 mg/mL (2.79 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7899 mL 13.9497 mL 27.8995 mL
5 mM 0.5580 mL 2.7899 mL 5.5799 mL
10 mM 0.2790 mL 1.3950 mL 2.7899 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.80 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.80 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (5.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在西域网站选购。
储存条件

主要用于各种急性严重细菌感染,严重过敏性疾病,胶原性疾病(红斑狼疮、结节性动脉周围炎等),风湿病、类风湿性关节炎、肾病综合征,严重支气管哮喘、血小板减少性紫癜、粒细胞减少症、急性淋巴性白血病、各种肾上腺皮质功能不全症、剥脱性皮炎、天皰疮、神经性皮炎、湿疹等。

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


符号 GHS08
GHS08
信号词 Warning
危害声明 H361
警示性声明 P281
个人防护装备 Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
危害码 (欧洲) Xn:Harmful
风险声明 (欧洲) R63
安全声明 (欧洲) S36/37/39-S45
危险品运输编码 NONH for all modes of transport
WGK德国 3
RTECS号 TU4154100
海关编码 2937210000

Section 1. Chemical Product and Company Identification
Prednisone
Common Name/
Trade Name
Prednisone

Section 4. First Aid Measures
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least
Eye Contact
15 minutes. Cold water may be used. WARM water MUST be used. Get medical attention if irritation occurs.
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Skin Contact
Serious Skin ContactNot available.
InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Not available.
Serious Inhalation
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
Ingestion
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Not available.
Serious Ingestion

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Not available.
Flash Points
Not available.
Flammable Limits
These products are carbon oxides (CO, CO2).
Products of Combustion
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards in
Slightly explosive in presence of open flames and sparks.
Presence of Various
Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
and Instructions
Material in powder form, capable of creating a dust explosion. As with most organic solids, fire is possible at elevated
Special Remarks on
temperatures
Fire Hazards
Fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust
Special Remarks on
explosion hazard.
Explosion Hazards

Section 6. Accidental Release Measures
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading
Small Spill
water on the contaminated surface and dispose of according to local and regional authority requirements.
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on
Large Spill
the contaminated surface and allow to evacuate through the sanitary system.
Prednisone

Section 7. Handling and Storage
Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not
Precautions
breathe dust. Wear suitable protective clothing. If you feel unwell, seek medical attention and show the label when
possible. Keep away from incompatibles such as oxidizing agents.
Keep container tightly closed. Keep container in a cool, well-ventilated area. Material should be stored at a
Storage
temperature less than 40 deg C., preferably between 15-30 deg. C.

Section 8. Exposure Controls/Personal Protection
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
Engineering Controls
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal ProtectionSafety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
of a Large Spill
handling this product.
Not available.
Exposure Limits

Section 9. Physical and Chemical Properties
Solid. (Solid crystalline powder.)Odorless.
Physical state andO dor
appearance
Bitter. Aftertaste.
Taste
358.43 g/mole
Molecular Weight
White or nearly white.
Color
Not available.
pH (1% soln/water)
Not available.
Boiling Point
Decomposition temperature: 230°C (446°F) - 235 C.
Melting Point
Not available.
Critical Temperature
Not available.
Specific Gravity
Not applicable.
Vapor Pressure
Not available.
Vapor Density
Not available.
Volatility
Not available.
Odor Threshold
Not available.
Water/Oil Dist. Coeff.
Not available.
Ionicity (in Water)
Not available.
Dispersion Properties
Very slightly soluble in cold water.
Solubility
Slightly soluble in methanol.
1 g soluble in 150 ml alcohol.
1 g soluble in 200 ml chloroform.

Section 10. Stability and Reactivity Data
The product is stable.
Stability
Not available.
Instability Temperature
Conditions of Instability Excess heat, incompatible materials.
Incompatibility with various Reactive with oxidizing agents.
substances
Prednisone
Non-corrosive in presence of glass.
Corrosivity
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
Will not occur.
Polymerization

Section 11. Toxicological Information
Inhalation. Ingestion.
Routes of Entry
Toxicity to AnimalsLD50: Not available.
LC50: Not available.
Chronic Effects on Humans CARCINOGENIC EFFECTS: 3 (Not classifiable for human.) by IARC.
MUTAGENIC EFFECTS: Mutagenic for bacteria and/or yeast.
Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Other Toxic Effects on
Humans
Not available.
Special Remarks on
Toxicity to Animals
May cause adverse reproductive effects and cancer based on animal test data.
Special Remarks on
Chronic Effects on Humans May affect genetic material (mutagenic).
Human: small amount excreted in maternal milk.
Acute Potential Health Effects:
Special Remarks on other
Skin: May cause skin irritation. May cause skin sensitization, an allergic reaction.
Toxic Effects on Humans
Eyes: May cause eye irritation.
Inhalation: May cause respiratory tract irritation.
Ingestion: May cause gastritis with nausea, vomiting, abdominal distention, ulcerative esophagitis, increased
sweating. May affect metabolism and cause disturbance of electrolyte balance which is manifest in the retention of
sodium and water, with edema and hypertension, and in the increased excretion of potassium with the possibility of
hypokalaemic alkalosis. Cardiac faillure may be induced in sensitive individuals.
Chronic Potential Health Effects:
Skin: Prolonged or repeated skin contact may cause sensitization, an allergic reaction.
Eyes: Prolonged contact with eyes may affect vision (cataracts)
Inhalation/Ingestion: May cause anaphylaxis, an allergic reaction. Prolonged or repeated inhalation or ingestion of
corticosteroids may also cause thinning of the skin, inpaired wound healing and other dermatologic reactions
(erythema, petechiae and ecchymoses).
Ingestion: Prolonged or repeated ingestion of corticosteroids may cause nausea, vomiting, abdominal distention,
peptic ulcer with possible perforation and hemorrhage, possible hypersensitization, swelling of the feet and lower legs
due to electrolyte imbalance and sodium retention, irregular hearbeat, acute adrenal insufficiency, osteoporosis,
muscle weakness, loss of muscle mass, vertebral compression fractures, pathologic fracture of long bones, aseptic
necrosis of femoral and humeral heads, effect glucose tolerance (causing decreased carbohydrate tolerance resulting
in manifestations of latent Diabetes melliltus, increased requirements for insulin or oral hypoglycemifcagents in
diabetes), the liver, pancreas (pancreatitis), eyes/vision (cataracts, glaucoma, increased intraocular pressure),
behavior/central nervous system/nervous system (mental disturbances such as psychosis, euphoria, depression, vertigo,
headache, convulsions, increased intracranial pressure with papilledema). It may also effect the immune system
(immunosuppressant). Repeated large doses of corticosteroids may produce Cushingoid symptoms typical of
hyperactivity of the adrenal cortex, with moon-face, sometimes hirsutism, buffalo hump, flushing, increased bruising,
ecchymoses, striae, and acne.
Medical Conditions Aggravated by Exposure: Hypersensivity to material, ocular herpes simplex, active alcoholism,
AIDS or HIV infection, heart disease or hypertension, diabetes mellitus, myasthenia gravis, impaired kidney or liver
function, esophagitis, gastritis or peptic ulcer, chickenpox or measles (including recent exposure), recent intestinal
surgery, tuberculosis, and system fungal infections.
Note: The above information came from Physicians GenRx - Drug Information, 1995 or was extrapolated from
information for Corticosteriods found in a reference called Martindale.
Prednisone

Section 12. Ecological Information
Not available.
Ecotoxicity
Not available.
BOD5 and COD
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The product itself and its products of degradation are not toxic.
Toxicity of the Products
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation

Section 13. Disposal Considerations
Waste must be disposed of in accordance with federal, state and local environmental control
Waste Disposal
regulations.

Section 14. Transport Information
Not a DOT controlled material (United States).
DO T Cl assi fi cati on
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DO T (Pi ctograms)

Section 15. Other Regulatory Information and Pictograms
New Jersey: Prednisone
Federal and State
TSCA 8(b) inventory: Prednisone
Regulations
California prop. 65: This product contains the following ingredients for which the State of California has found to
California
cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause birth defects which would require a warning under the statute: No products were found.
EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS No.
Other Regulations
200-160-3).
Canada: Listed on Canadian Non-Domestic Substance List (NDSL).
China: Not listed on National Inventory.
Japan: Listed on National Inventory (ENCS).
Korea: Listed on National Inventory (KECI).
Philippines: Not listed on National Inventory (PICCS).
Australia: Listed on AICS.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
Not availableNot applicable.
DSCL (EEC)
Health Hazard
HMIS (U.S.A.)1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity0
Specific hazard
Personal Protection
E
Prednisone
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG(Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or equivalent.
Prednisone
CALL (310) 516-8000
Notice to Reader
All chemicals may pose unknown hazards and should be used withcaution. This Material Safety Data Sheet (MSDS) applies only to the material as packaged. If this product is combined with other materials,
deteriorates, or becomes contaminated, it may pose hazards not mentioned inthis MSDS. It shall be the user's responsibility to develop proper methods of handling and personal protection based onthe actual


SECTION 16 - ADDITIONAL INFORMATION
N/A

~88%

53-03-2结构式

53-03-2

文献:Wang, Shao-Min; Zhang, Yan-Bing; Liu, Hong-Min; Yu, Guo-Bin; Wang, Ke-Rang Steroids, 2007 , vol. 72, # 1 p. 26 - 30

~%

53-03-2结构式

53-03-2

文献:Kruszewska; Chmielowiec; Uszycka-Horawa Farmaco, 1996 , vol. 51, # 12 p. 809 - 810

~%

53-03-2结构式

53-03-2

文献:Hogg et al. Journal of the American Chemical Society, 1955 , vol. 77, p. 4436

~%

53-03-2结构式

53-03-2

文献:Hogg et al. Journal of the American Chemical Society, 1955 , vol. 77, p. 4436

~%

53-03-2结构式

53-03-2

文献:Schering Corp. Patent: US2837464 , 1955 ; Full Text Show Details Herzog et al. Tetrahedron, 1962 , vol. 18, p. 581,588

~%

53-03-2结构式

53-03-2

文献:Szpilfogel et al. Recueil des Travaux Chimiques des Pays-Bas, 1956 , vol. 75, p. 475,480

~%

53-03-2结构式

53-03-2

文献:Kane; Tsuji Journal of Pharmaceutical Sciences, 1983 , vol. 72, # 1 p. 30 - 35

服务热线

13911702513
18601927057

微信客服